Suppr超能文献

利用免疫信息学方法设计针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的刺突蛋白(S)和核衣壳蛋白(N)的多表位肽疫苗。

Design of a multi-epitope-based peptide vaccine against the S and N proteins of SARS-COV-2 using immunoinformatics approach.

作者信息

Rouzbahani Arian Karimi, Kheirandish Farnaz, Hosseini Seyedeh Zeinab

机构信息

Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.

Department of Medical Parasitology and Mycology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

出版信息

Egypt J Med Hum Genet. 2022;23(1):16. doi: 10.1186/s43042-022-00224-w. Epub 2022 Feb 4.

Abstract

BACKGROUND

As the new pandemic created by COVID-19 virus created the need of rapid acquisition of a suitable vaccine against SARS-CoV-2 to develop Immunity and to reduce the mortality, the aim of this study was to identify SARS-CoV-2 S protein and N antigenic epitopes by using immunoinformatic methods to design a vaccine against SARS-CoV-2, for which S and N protein-dependent epitopes are predicted. B cell, CTL and HTL were determined based on antigenicity, allergenicity and toxicity that were non-allergenic, non-toxic, and antigenic and were selected for the design of a multi-epitope vaccine structure. Then, in order to increase the safety of Hbd-3 and Hbd-2 as adjuvants, they were connected to the N and C terminals of the vaccine construct, respectively, with a linker. The three-dimensional structure of the structure was predicted and optimized, and its quality was evaluated. The vaccine construct was ligated to MHCI. Finally, after optimizing the codon to increase expression in K12, the vaccine construct was cloned into pET28a (+) vector.

RESULTS

Epitopes which were used in our survey were based on non-allergenic, non-toxic and antigenic. Therefore, 543-amino-acid-long multi-epitope vaccine formation was invented through linking 9 cytotoxic CTL, 5 HTL and 14 B cell epitopes with appropriate adjuvants and connectors that can control the SARS coronavirus 2 infection and could be more assessed in medical scientific researches.

CONCLUSION

We believe that the proposed multi-epitope vaccine can effectively evoke an immune response toward SARS-CoV-2.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1186/s43042-022-00224-w.

摘要

背景

由于新冠病毒引发的新疫情产生了快速获取针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的合适疫苗以产生免疫力并降低死亡率的需求,本研究的目的是通过免疫信息学方法鉴定SARS-CoV-2刺突蛋白(S蛋白)和核衣壳蛋白(N蛋白)的抗原表位,以设计一种针对SARS-CoV-2的疫苗,其中预测了依赖S蛋白和N蛋白的表位。基于抗原性、致敏性和毒性确定了B细胞、细胞毒性T淋巴细胞(CTL)和辅助性T淋巴细胞(HTL)表位,这些表位无致敏性、无毒性且具有抗原性,并被选用于设计多表位疫苗结构。然后,为了提高人β-防御素3(Hbd-3)和人β-防御素2(Hbd-2)作为佐剂的安全性,它们分别通过一个接头连接到疫苗构建体的N端和C端。预测并优化了该结构的三维结构,并评估了其质量。将疫苗构建体连接到主要组织相容性复合体I类分子(MHCI)上。最后,在优化密码子以增加在大肠杆菌K12中的表达后,将疫苗构建体克隆到pET28a(+)载体中。

结果

我们研究中使用的表位基于无致敏性、无毒性且具有抗原性。因此,通过将9个细胞毒性CTL表位、5个HTL表位和14个B细胞表位与合适的佐剂和接头连接,发明了一种长度为543个氨基酸的多表位疫苗,该疫苗可以控制SARS冠状病毒2感染,并且可以在医学科研中进行更多评估。

结论

我们认为所提出的多表位疫苗可以有效引发针对SARS-CoV-2的免疫反应。

补充信息

在线版本包含可在10.1186/s43042-022-00224-w获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7801/8813187/d8d579dd7105/43042_2022_224_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验